Flux Therapeutics Flux Therapeutics develops genetic medicines for haploinsufficiency and other inherited disorders that are difficult to address with existing gene therapies. Its platform combines targeted ubiquitin modulators, or TUMs, with other therapeutic technologies to overcome limitations of first-generation genetic medicines. Haploinsufficiency occurs when a single functional copy of a gene does not provide enough gene product for normal biological function. The company is a Scion Life Sciences portfolio business. The public site describes a development platform rather than approved medicines and does not disclose an approved product, specific clinical program or completed trial.
team@apexlogos.ai · 19 hours ago
Undisclosed actual Scion holding record, no exact equity financing announcement recovered. Amount/date/stage unknown; stage label explicitly marks this as published portfolio investment. No personal Lalo/Andreas ticket and no specific Fund I participation inferred. April17,2025 USD140m-plus aggregate first-wave commitments include Scion AND syndicate partners and multiple anonymous companies, so no aggregate amount assigned to Flux. February2024 four anonymous builds and April2025 three anonymous builds may overlap and cannot be summed or represented as invented startups. Source: https://www.scionlifesciences.com/news/scion-life-sciences-expands-team-with-appointment-of-three-venture-partners SHOW MORE
team@apexlogos.ai · 19 hours ago
Full public own website bios recovered through public web-search cache last crawled about two months before review list three named leadership relationships. Direct live HTTP fetch is blocked by public CAPTCHA; freshly extracted own homepage contains platform description but no roster. Lalo’s CEO role is separately current on Scion’s own site. Andreas and Suyash are preserved as own published leadership with current-status freshness explicitly unconfirmed; no invented dismissal, replacement or departure. No board or scientific-adviser roster found in bounded own-source review. This is the complete recovered published roster, not a claim of complete headcount. Exact company founding year undisclosed; September2023 trademark application and earlier patent priorities are not corporate founding dates. Flux Therapeutics LLC of Blacksburg Virginia, UEI HC3CAHM3NQ68, develops SPNS2 inhibitors for renal fibrosis and received a USD301,373 NIH/STTR grant; no proven legal link to the Scion TUM genetic-medicine company. Do not merge or assign that grant. Existing native Flux at flux.ai is a separate AI hardware company, and Flux Computing at fluxcomputing.com is also unrelated. SCN2A Foundation 2024 industry roundtable lists Suyash Prasad representing Flux, but conference participation alone does not establish a specific SCN2A program, clinical approval or trial result. Secondary PRPF8/neurology pipeline claims are not promoted without an exact primary issuer program disclosure. Sources: https://flux-therapeutics.com/ ; https://www.scionlifesciences.com/team/investment-team/lalo-flores-phd ; https://ttabvue.uspto.gov/ttabvue/ttabvue-92085858-CAN-1.pdf ; https://www.sbir.gov/portfolio/1542627 ; https://www.scn2a.org/pdf/2024%20-%20FamilieSCN2A%20Foundation%20Research%20Roundtable%20_%20FINAL%20%283%29.pdf SHOW MORE
